Investor Presentaiton

TYVYTⓇ as Leading PD-1 brand in China Market with Unveiled Huge Potentials in Global Markets RMB mn 2,500 2,000 1,500 Strong sales growth since launch First-mover Advantage Comprehensive Development Strategy Innovent [新 Shee 信迪利单抗注射液 Sintilimab Injection 10ml:100mg 信惠利单抗注射液 10ml: 100mg RMB 2,290mn Out-license Partnership with Eli Lilly Maintain strong leadership position in China market Backbone role for oncology TA Best positioned to explore huge potential in global markets • First PD-1 included in NRDL in 2019 RMB 1,016mn • Strong revenue growth and leading market share 1,000 500 NMPA approval in Dec 2018 New indication approvals on large cancers upcoming: 1L nsq NSCLC (approved in Feb 2021), 1L sqNSCLC, 1L HCC, 2L sqNSCLC • • The first marketed China PD-1 out-licensed to global MNC pharmaceutical company Eli Lilly plans to file BLA (NSCLC) in 2021 • Expand to external new combos • Extensive network and experienced marketing and • sales team (>1500 ppl) Combo/Bispecific with internal pipeline (CTLA-4, TIGIT, FGFR, LAG-3, VEGF etc) • Global PD-1 market size and valuation multiple times larger than that in China market • Manufacturing capacity: 24,000L in operation and additional 36,000L in construction • Achieve the breakthrough and focus on 4 key tumor types (Lung, Liver, Gastric, Esophagus) 2018 2019 2020 Innovent is confident to maintain TYVYTⓇ as the leading PD-1 brand in China market and is best positioned to capture the much larger potential in global markets. Innovent Confidential Copyright©2021 Innovent Biologics 6

View entire presentation